Fennec Pharms

FENC NASDAQ
4.070
-0.340
-7.71%
Closed 16:00 08/23 EDT
Open
4.395
Prev Close
4.410
High
4.395
Low
3.910
Volume
25.62K
Avg Vol (3M)
86.04K
52 Week High
10.08
52 Week Low
3.255
% Turnover
0.14%
Market Cap
74.95M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Fennec Pharms FENC stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
MORE >

Recently

Name
Price
%Change